Author: zimet

Pembrolizumab and mesothelioma

Pembrolizumab appears to be an active drug in the treatment of mesothelioma. About 25% of patients have reduction in tumour whilst another 30% have stabilisation of disease. On average this lasts 6 months. Other immunomodulating drugs may also be effective.

The treatment however is costly.

Low dose aspirin reduces risk of recurrence of colon cancer

A study in the Annals of Internal Medicine (Aug 24 2015) found that in a group of Danish patients who after colon cancer took low dose aspirin or NSAID there was a 27% reduced risk of colon cancer recurrence.

This effect was seen in the group who took the medication long term.

Dr Zimet thinks that this may be a reasonable treatment for patients with prior colon cancer if there is no contraindication to therapy.

Read further here.